Clinical outcomes of cancer immunotherapy with immune-checkpoint inhibitors (ICIs) for non-small cell lung cancer appear to be highly correlated with level of plasma PD-L1-EVs, in which non-responders show elevated level of plasma PD-L1-EVs compared to responders [163]. The gene discussed is CD274; the disease is cancer.